NCT02779881

Brief Summary

Epigenetic mechanisms have been implicated in the pathogenesis of food allergy. The investigators previously demonstrated that tolerance acquisition in children with Immunoglobulin E- (IgE) mediated cow's milk allergy (CMA) is driven by epigenetic modulation of the Th1 and Th2 cytokine genes. A regulatory T cell (Treg) suppressive phenotype, characterized by stable expression of the transcription factor "Forkhead box Protein 3" (FoxP3), plays a pivotal role in food tolerance. FoxP3 mRNA expression is lower in children with atopic asthma or IgE-mediated food allergy than in healthy children. FoxP3 stable expression requires full CpG demethylation of its transcriptional regulatory regions, and, moreover, hypermethylation of the FoxP3 gene has been associated with reduced Treg function and allergy. DNA methylation is a biologically and chemically stable epigenetic modification that locks in long-term gene expression patterns. The demethylation status of FoxP3 at a highly conserved region within the Treg-specific-demethylated-region (TSDR), a CpG-rich, located on the 2nd conserved non-coding sequence of FoxP3 (CNS2), is restricted to Tregs. Transcriptional activity of the TSDR is essentially determined by its methylation status : it is completely inactive in its methylated state, but when the TSDR is demethylated, transcription factors such as Ets-1 and Creb can bind to the TSDR. TSDR demethylated and open chromatin conformation in the Foxp3 locus leads to stable phenotype differentiated Foxp3+ Treg. FoxP3 TSDR demethylation in peripheral blood mononuclear cells (PBMCs) has been associated with reduced atopic sensitization and asthma in children. Epigenetic regulation of antigen-induced T-cell subsets may predict a state of immune tolerance in food allergy. Indeed, DNA methylation of the FoxP3 gene in Tregs decreased during oral tolerance acquisition in patients with peanut allergy undergoing oral immunotherapy. The aim of this study was to evaluate further the epigenetic regulation of FoxP3 gene in children with IgE-mediated CMA.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2014

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

May 16, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 23, 2016

Completed
Last Updated

May 23, 2016

Status Verified

May 1, 2016

Enrollment Period

1.3 years

First QC Date

May 16, 2016

Last Update Submit

May 19, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • DNA demethylation (rate, in %) of the Treg-specific-demethylated-region (TSDR) of FoxP3

    At enrollment

Study Arms (4)

Healthy controls

Healthy controls

Children at diagnosis of cow's milk allergy

Children at diagnosis of cow's milk allergy

Subjects outgrown cow's milk allergy with formula+probiotic

Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG

Dietary Supplement: Extensively hydrolyzed casein formula plus LGG

Subjects outgrown cow's milk allergy assuming other formulas

Subjects tolerant with other formulas

Interventions

Subjects outgrown cow's milk allergy with formula+probiotic

Eligibility Criteria

Age3 Months - 18 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

IgE-mediated CMA children (aged 3 to 18 months) consecutively referred to the tertiary Pediatric Allergy Center for oral food challenge. During the same study period, consecutive healthy children, not at risk of atopic disorders (namely, those without a first-degree relative affected by an atopic disorder), attending the Center because of minimal surgical procedures served as a control group. A venous blood sample (4 ml) was obtained from all patients after oral challenge.

You may qualify if:

  • IgE-mediated CMA children (aged 3 to 18 months)

You may not qualify if:

  • allergic disorders or food allergies other than cow's milk allergy
  • eosinophilic disorders of the gastrointestinal tract
  • food protein-induced enterocolitis syndrome
  • concomitant chronic systemic diseases
  • congenital cardiac defects
  • active tuberculosis
  • autoimmune diseases
  • immunodeficiency
  • chronic inflammatory bowel diseases
  • celiac disease
  • cystic fibrosis
  • metabolic diseases
  • lactose intolerance
  • malignancy
  • chronic pulmonary diseases
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Naples Federico II

Naples, 80131, Italy

Location

Related Publications (1)

  • Paparo L, Nocerino R, Cosenza L, Aitoro R, D'Argenio V, Del Monaco V, Di Scala C, Amoroso A, Di Costanzo M, Salvatore F, Berni Canani R. Epigenetic features of FoxP3 in children with cow's milk allergy. Clin Epigenetics. 2016 Aug 12;8:86. doi: 10.1186/s13148-016-0252-z. eCollection 2016.

MeSH Terms

Conditions

Milk Hypersensitivity

Condition Hierarchy (Ancestors)

Food HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD

Study Record Dates

First Submitted

May 16, 2016

First Posted

May 23, 2016

Study Start

December 1, 2012

Primary Completion

April 1, 2014

Study Completion

April 1, 2014

Last Updated

May 23, 2016

Record last verified: 2016-05

Data Sharing

IPD Sharing
Will not share

Locations